Simbolo: LLY

Eli Lilly

Farmaceutico Sanità Produttori farmaceutici - generici

Prezzo 1222.61

Racc. Compra Potenziale 83 Rischio 28 Aggiornato 2026-07-27

Sito ufficiale

Impatto della previsione

positivo

Target +15.6% raggiungimento target 86.5%

Reazione D5 +0.63% · D10 +2.64% recente confermato · fiducia mercato

Impatto Potenziale +6 · Rischio -3 valido fino a 2026-08-13

Traccia in portafoglio

Grafico prezzo

Raccomandazione AI Previsione analista Evento calendario Segnale positivo Segnale negativo Neutrale / aggiornamento Mantieni / informativo B Il mio acquisto S La mia vendita

Descrizione

Società e modello di business

Eli Lilly è un'azienda globale nel settore della salute che si concentra sulla scoperta, sviluppo e commercializzazione di farmaci. I suoi prodotti principali includono trattamenti per il diabete, oncologia, immunologia e malattie neurodegenerative. I principali segmenti di business consistono nella cura del diabete, oncologia e neuroscienze, con significativi ricavi generati dai prodotti a base di insulina e dalle terapie oncologiche. L'azienda è riconosciuta per il suo innovativo pipeline di farmaci e la forte presenza sul mercato nel settore sanitario.

Profilo di investimento

Le azioni di Eli Lilly sono posizionate come un investimento bilanciato, attraente per gli investitori che cercano una crescita moderata e un certo reddito attraverso i dividendi. L'azienda dimostra una crescita dei ricavi stabile e un rendimento da dividendi costante, rendendola adatta a coloro che cercano un mix di apprezzamento del capitale e reddito. La sua presenza consolidata sul mercato e lo sviluppo continuo dei prodotti contribuiscono a un profilo di rischio-rendimento favorevole.

Categoria: Farmaceutico Settore: Sanità Industria: Produttori farmaceutici - generici Stile di investimento: Crescita Orizzonte: Lungo termine Tipo di società: Blue Chip Tipo di società: Leader di mercato Esperienza: Base

Metriche fondamentali (sperimentale) Aggiornato: 2026-07-24

EPS (TTM) — utile per azione degli ultimi 12 mesi, $: 28.20
Ricavi QoQ — crescita dei ricavi trimestre su trimestre: 2.6%
Sorpresa EPS: 22.7%
Volatilità 20g: 1.6%
Rendimento dividendo: 0.7%
ultima data ex-dividendo: 2026-08-14

Cambiamenti di raccomandazione AI

Data	Prima	Dopo	Motivo
2026-05-18	Mantieni	Compra	Strong fundamentals and positive short-term momentum.
2026-05-10	Compra	Mantieni	Weak momentum and high risk; mixed analyst signals.
2026-05-08	—	Compra	Solid fundamentals but mixed momentum signals.
2026-05-08	Compra	Compra	Компания показывает стабильный рост выручки и положительные сюрпризы по EPS, однако недавние колебания цен и негативная динамика на более длительных сроках вызывают осторожность.
2026-04-29	Mantieni	Compra	Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по прибыли, однако недавние колебания цен акций и снижение на более длительных горизонтах вызывают опасения. Рекомендуется удерживать акции
2026-04-17	Compra	Mantieni	Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по EPS, однако недавние колебания цен акций и снижение на коротких временных интервалах могут указывать на повышенные риски.
2026-04-09	Mantieni	Compra	Компания Eli Lilly демонстрирует стабильный рост выручки и положительные результаты по EPS, что указывает на сильные финансовые показатели. Несмотря на недавние колебания цен, долгосрочные тренды и позитивные прогнозы де
2026-03-22	Compra	Mantieni	Компания Eli Lilly демонстрирует сильный рост выручки и положительный сюрприз по прибыли, однако недавнее снижение цен акций и высокая волатильность могут указывать на риски в краткосрочной перспективе.
2026-02-06	Mantieni	Compra	Компания Eli Lilly демонстрирует сильный рост за последние 120 дней, однако недавнее падение на 7.79% может указывать на краткосрочные риски. Рекомендуется удерживать акции до более ясной картины.
2026-01-29	Compra	Mantieni	Компания Eli Lilly демонстрирует сильный рост за последние 60 и 120 дней, однако недавние колебания цен указывают на возможную волатильность. Рекомендуется удерживать акции до более ясных сигналов о дальнейшем движении.

Previsioni analisti

Data	Analista	Action	Target	Prezzo allora
2026-07-14	Bernstein	Target alzato	— → 1385	1185.08
2026-07-13	UBS	Target alzato	1250 → 1425	1189.91003
2026-07-13	Guggenheim	Target alzato	— → 1273	1188.58
2026-07-09	UBS	Target alzato	1281 → 1370	1222.125
2026-07-08	Truist Financial	Target alzato	— → 1370	1227.07
2026-07-08	RBC Capital	Target alzato	1250 → 1500	1229.21997
2026-07-08	Morgan Stanley	Target alzato	1344 → 1347	1235.56
2026-07-06	Cantor Fitzgerald	Target alzato	— → 1350	1210.5
2026-06-25	Leerink Partners	Target alzato	1119 → 1232	1117.26
2026-06-22	Berenberg Bank	Target alzato	1050 → 1135	1111.67
2026-06-09	Jefferies	Target alzato	1330 → 1350	1143.35
2026-05-26	HSBC	Target alzato	— → 1251	1065
2026-05-26	Leerink Partners	Aggiorna	— → 1119	1065
2026-05-21	Wolfe Research	Target alzato	1325 → 1350	1037.82007
2026-05-05	Barclays	Target alzato	1350 → 1400	967.93
2026-05-01	Morgan Stanley	Target alzato	1327 → 1344	961.555
2026-05-01	Cantor Fitzgerald	Target alzato	1205 → 1230	970.675
2026-04-10	Morgan Stanley	Target alzato	1313 → 1327	939.31
2026-03-13	Jefferies	Aggiorna	— → 1300	1000.78003
2026-03-06	Deutsche Bank	Aggiorna	— → 1285	990.31
2026-03-05	Morgan Stanley	Aggiorna	— → 1313	972.5

Notizie Pagina 3 di 4

Novo Nordisk and Eli Lilly Compete for Dominance in the GLP-1 Pill Market Ahead of Medicare Coverage

06/08/2026, 10:48 AM business review healthcare Novo Nordisk Eli Lilly

Novo Nordisk and Eli Lilly are intensifying their competition in the GLP-1 pill market as they prepare for Medicare coverage, which could significantly increase access to their obesity treatments. Both companies are focusing on marketing strategies to appeal to seniors, who will soon be able to access these medications at a reduced cost.

Stock Market Experiences Significant Decline Following Strong Jobs Report and Disappointing Earnings from Tech Companies

06/06/2026, 10:32 AM economy review tech semiconductors SpaceX Wells Fargo Intel Broadcom Eli Lilly

Last week's stock market experienced a significant downturn, primarily driven by disappointing earnings from major tech companies and a strong jobs report that diminished expectations for a Federal Reserve interest rate cut. This shift has raised concerns about the sustainability of recent market highs and the potential impact of increased stock supply from upcoming IPOs.

Cramer Highlights Buying Opportunity in AI Stocks Amid Market Cooling

06/05/2026, 10:33 AM economy review ai tech CrowdStrike Holdings SpaceX Cardinal Health Intel Johnson & Johnson Apple Broadcom Eli Lilly

The recent decline in stock prices, particularly in the tech sector, presents a potential buying opportunity for investors, especially in chip stocks and AI-related companies, according to Jim Cramer.

Dow Jones Industrial Average Hits Record High as Health-Care Stocks Lead Market Gains

06/05/2026, 05:34 AM business review healthcare UnitedHealth Humana Centene Eli Lilly

Despite a decline in chip stocks, the U.S. stock market saw significant gains, with the Dow Jones Industrial Average reaching a new record, driven largely by strong performance in the health-care sector.

Jim Cramer Suggests Trimming Goldman Sachs (GS) and Wells Fargo (WFC) Positions for Different Reasons

06/04/2026, 09:31 AM economy review finance CrowdStrike Holdings Goldman Sachs Wells Fargo Johnson & Johnson Eli Lilly

Investors are witnessing a sector rotation from AI hardware to healthcare and financials, with notable movements in stocks like Goldman Sachs and CrowdStrike, indicating shifting market dynamics.

Eli Lilly’s Business Development Head Jacob Van Naarden Signals Increased M&A Activity as Company Pursues New Opportunities

06/03/2026, 04:33 AM business announcement healthcare Eli Lilly

Eli Lilly is leveraging its significant financial strength, driven by its successful weight loss drugs, to pursue an aggressive acquisition strategy aimed at diversifying its drug pipeline and expanding into new therapeutic areas. This shift marks a notable change in Lilly's approach to dealmaking as it seeks to capitalize on its recent growth.

Analysts JPMorgan recommend top stocks for June, including Viasat (VSAT) and Eli Lilly (LLY)

06/02/2026, 08:31 AM investing recommendation Analysts: analysts, JPMorgan software telecom Viasat Eli Lilly

JPMorgan's updated list of top investment ideas for June highlights strong performance in U.S. stocks, particularly in technology, and includes new recommendations such as Viasat, which has seen significant growth despite recent volatility.

CVS Health to Restore Coverage of Eli Lilly’s Zepbound and Add Foundayo Obesity Pill to Drug Plans

05/28/2026, 04:34 AM business announcement healthcare CVS Health Eli Lilly

CVS Health's decision to restore coverage for Eli Lilly's Zepbound and add its new obesity pill Foundayo is significant as it enhances patient access to weight loss treatments and strengthens Lilly's competitive position against Novo Nordisk in the market.

Stocks to Watch: AutoZone Declines on Sales Challenges, Eli Lilly Acquires Three Companies, Ferrari Launches Electric Vehicle, and Lear Upgraded by TD Cowen

05/26/2026, 05:34 AM business review auto pharma Micron Advanced Micro Devices Exxon Mobil Intuitive Machines AutoZone Ferrari Chevron Qualcomm Eli Lilly

Several companies are experiencing notable stock movements ahead of the market opening, with AutoZone facing declines due to disappointing international sales, while Eli Lilly's acquisition strategy boosts its stock.

Eli Lilly (LLY) Plans Nearly $4 Billion in Vaccine Acquisitions to Expand Infectious Disease Research

05/26/2026, 05:34 AM announcement healthcare Eli Lilly

Eli Lilly's announcement to acquire three companies for nearly $4 billion highlights its strategic shift towards infectious disease research, which could enhance its market position in vaccine development.